Clever leaves Holdings Inc. announced that its Colombian flower is now available to patients in Australia through a partnership with Australian Natural Therapeutics Group. The products are available to medical patients in Australia under ANTG's "Global Selects" brand portfolio. Clever leaves provides a sustainable, reliable, and cost-effective supply of pharmaceutical-grade cannabinoids and active pharmaceutical ingredients from its EU GMP certified cultivation facility in Colombia to more than 15 countries across the globe.

ANTG's evolving brand portfolio signifies its commitment to providing Australian patients with a consistent supply of medicinal-grade plant medicine. The new 'Global Selects' range is widely available through pharmacy outlets across the country. In Australia, medical cannabis is used to treat thousands of patients each year for conditions including anxiety, inflammation, seizures, and pain management.

According to official data from the Therapeutic Goods Administration (TGA), in 2022 there were 319,000 reported patients, while in 2021 this number was 150,000. Additionally, interest in local clinical research to test the efficacy of cannabinoid products for numerous medical conditions is increasing. Current research areas include sleep apnea, PTSD, cancer, depression, and dementia, among others.